At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
N-Acetyl cysteinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients
In Brief
A Phase 2 clinical trial evaluating N-Acetyl cysteine for Traumatic Brain Injury. Completed, enrolled 92 participants across 2 sites.
Detailed Summary
This study will evaluate the administration of N-Acetyl-cysteine in combination with multi-vitamins/minerals in geriatric population (\>60 years of age) who have experienced a traumatic brain injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTraumatic Brain Injury
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedMar 2020
Primary CompletionApr 2020
Study CompletionAug 2021
TodayJul 2026
First PostedMar 2, 2020
Enrollment StartSep 1, 2019
Primary CompletionApr 30, 2020
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.3 years ago
Interventions
N-Acetyl cysteinedrug
Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI